Dötetrabenazin etkileşimleri

Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (Amiodaron etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (Azitromisin etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (Dofetilid etiketi, Uyarılar)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (Emtrisitabin, rilpivirin ve tenofovir etiketi, Uyarılar ve önlemler)

Taking monoamine oxidase inhibitors (MAOIs). (Dötetrabenazin etiketi, Kontrendikasyonlar)

Drugs that Prolong the QT Interval : Avoid concomitant use. (Fenobarbital etiketi, İlaç etkileşimleri)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (Flukonazol etiketi, Kontrendikasyonlar)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (Fosfomisin etiketi, İlaç etkileşimleri)

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (Foskarnet etiketi, İlaç etkileşimleri)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (Hidroksiklorokin etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (İvabradin etiketi, Uyarılar ve önlemler)

Taking monoamine oxidase inhibitors (MAOIs). (Dötetrabenazin etiketi, Kontrendikasyonlar)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (Levofloksasin etiketi, Uyarılar ve önlemler)

Taking monoamine oxidase inhibitors (MAOIs). (Dötetrabenazin etiketi, Kontrendikasyonlar)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval. (Lopinavir ve ritonavir etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Taking monoamine oxidase inhibitors (MAOIs). (Dötetrabenazin etiketi, Kontrendikasyonlar)

Examples diazepam, alprazolam, alcohol Drugs that Prolong QTc Interval Clinical Impact The concomitant use of other drugs which prolong the QTc interval with REMERON/REMERONSolTab, increase the risk of QT prolongation and/or ventricular arrhythmias (e.g., Torsades de Pointes). (Mirtazapin etiketi, İlaç etkileşimleri)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (Oksaliplatin etiketi, İlaç etkileşimleri)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib etiketi, İlaç etkileşimleri)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (Pitolisant etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (Propafenon etiketi, Uyarılar ve önlemler)

Taking monoamine oxidase inhibitors (MAOIs). (Dötetrabenazin etiketi, Kontrendikasyonlar)

Examples: beta-blockers, clonidine, guanethidine, and reserpine Clopidogrel : Avoid concomitant use; if used concomitantly initiate at 0.5 mg before each meal and limit total daily dose to 4 mg ( 7 ) (Repaglinid etiketi, İlaç etkileşimleri)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Taking monoamine oxidase inhibitors (MAOIs). (Dötetrabenazin etiketi, Kontrendikasyonlar)

Avoid the concomitant use of drugs known to prolong the QTc interval. (Sertralin etiketi, İlaç etkileşimleri)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (Siprofloksasin etiketi, Uyarılar ve önlemler)

Taking tetrabenazine or valbenazine [see Drug Interactions ( 7.6 )] . (Dötetrabenazin etiketi, Kontrendikasyonlar)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Taking monoamine oxidase inhibitors (MAOIs). (Dötetrabenazin etiketi, Kontrendikasyonlar)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Taking tetrabenazine or valbenazine [see Drug Interactions ( 7.6 )] . (Dötetrabenazin etiketi, Kontrendikasyonlar)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (Vepdegestrant etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (Arformoterol etiketi, İlaç etkileşimleri)

Drug Interactions Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with β-blocking agents. (Asebutolol etiketi, İlaç etkileşimleri)

Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. (Atenolol etiketi, İlaç etkileşimleri)

Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e.g., reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. (Atenolol ve klortalidon etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents. (Betaksolol etiketi, İlaç etkileşimleri)

Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. (Bisoprolol etiketi, İlaç etkileşimleri)

Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored because the added beta-adrenergic blocking action of bisoprolol fumarate may produce excessive reduction of sympathetic activity. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Catecholamine-depleting Drugs Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (Brimonidin ve timolol etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (Dorzolamid ve timolol etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between efavirenz and drugs that prolong the QTc interval. (Efavirenz etiketi, İlaç etkileşimleri)

QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between EFV and drugs that prolong the QTc interval. (Efavirenz, lamivudin ve tenofovir etiketi, İlaç etkileşimleri)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (Eribulin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

…that Antagonize the Pressor Effect The increasing blood pressure effect of BIORPHEN is decreased in patients receiving: α-adrenergic antagonists Phosphodiesterase Type 5 inhibitors Mixed α- and β-receptor antagonists Calcium channel blockers, such as nifedipine Benzodiazepines ACE inhibitors Centrally acting sympatholytic agents, such as reserpine, guanfacine (Fenilefrin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

…Antidepressants, QTc Prolonging Drugs Formoterol, as with other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (Formoterol etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

The signs of hypoglycemia may be reduced or absent in patients taking sympatholytic drugs such as beta-blockers, clonidine, guanethidine, and reserpine. (Glimepirid etiketi, İlaç etkileşimleri)

The signs of hypoglycemia may be reduced or absent in patients taking sympatholytic drugs such as beta-blockers, clonidine, guanethidine, and reserpine. (Glipizid etiketi, İlaç etkileşimleri)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (Goserelin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine and reserpine Intervention: Increased frequency of glucose monitoring may be required when Insulin Aspart is concomitantly administered with these drugs. (İnsülin aspart etiketi, İlaç etkileşimleri)

Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine, and reserpine Intervention: Increased frequency of glucose monitoring may be required when Insulin Degludec is co-administered with these drugs. (İnsülin degludek etiketi, İlaç etkileşimleri)

Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine, and reserpine Intervention: Increased frequency of glucose monitoring may be required when LEVEMIR is co-administered with these drugs. (İnsülin detemir etiketi, İlaç etkileşimleri)

Drugs that May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine, and reserpine. (İnsülin glarjin etiketi, İlaç etkileşimleri)

Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine, and reserpine. (İnsülin lispro etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (Karvedilol etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Postganglionic Blocking Agents Agents such as reserpine potentiate cocaine-induced sympathetic stimulation; concurrent use may increase the risk of hypertension and cardiac arrhythmias that may be life-threatening. (Kokain etiketi, İlaç etkileşimleri)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

TYKERB may prolong the QT interval in some patients. (Lapatinib etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (Löprolid etiketi, Uyarılar ve önlemler)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (Meflokin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Catecholamine depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. (Metoprolol etiketi, İlaç etkileşimleri)

Drug Interactions with Metoprolol Catecholamine Depleting Drugs: The concomitant use of catecholamine-depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) with beta adrenergic blockers may have an additive affect and increase the risk of hypotension or bradycardia CYP2D6 Inhibitors: Drugs that are strong inhibitors of CYP2D6 such as quinidine,… (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (Metronidazol etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

There is little or no experience with high exposure, concomitant dosing with other QT-prolonging drugs, or potassium channel variants resulting in a long QT interval. [See Warnings & Precautions ( 5.6 )] To minimize risk, the lowest effective dose should always be used. (Mifepriston etiketi, Uyarılar ve önlemler)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (Moksifloksasin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Catecholamine-depleting drugs (e.g., reserpine) - additive effect; monitor closely for evidence of hypotension and/or excessive bradycardia (e.g., vertigo, syncope, postural hypotension). (Nadolol etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: beta-blockers, clonidine, guanethidine, and reserpine Intervention: Increased frequency of glucose monitoring may be required when nateglinide is coadministered with these drugs. (Nateglinid etiketi, İlaç etkileşimleri)

Reserpine or clonidine may produce excessive reduction of sympathetic activity. (Nebivolol etiketi, İlaç etkileşimleri)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (Pasireotid etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. (Pindolol etiketi, İlaç etkileşimleri)

The signs of hypoglycemia may be reduced or absent in patients taking sympatholytic drugs such as beta-blockers, clonidine, guanethidine, and reserpine. (Pioglitazon ve glimepirid etiketi, İlaç etkileşimleri)

Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (Ponesimod etiketi, İlaç etkileşimleri)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (Primakin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Mechanism and Clinical Effect(s) Concomitant use of pentamidine with AFREZZA may cause hypoglycemia, which may sometimes be followed by hyperglycemia Beta-blockers, Clonidine, Guanethidine, and Reserpine Prevention or Management Monitor blood glucose more frequently and modify AFREZZA dosage, as clinically indicated, when used concomitantly with these drugs. (Regüler insülin (insan) etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (Rilpivirin etiketi, Uyarılar ve önlemler)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (Rokuronyum etiketi, Uyarılar ve önlemler)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Avoid use of Citalopram Capsules in patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure and patients taking other drugs that prolong the QTc interval. (Sitalopram etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (Sotalol etiketi, İlaç etkileşimleri)

Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (Timolol etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (Triptorelin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Examples of acidifying agents include gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid hydrochloride, ascorbic acid) and urinary acidifying agents (e.g., ammonium chloride, sodium acid phosphate, methenamine salts). (Dekstroamfetamin etiketi, İlaç etkileşimleri)

Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (Efedrin etiketi, İlaç etkileşimleri)

Phenoxybenzamine hydrochloride blocks hyperthermia production by levarterenol, and blocks hypothermia production by reserpine. (Fenoksibenzamin etiketi, İlaç etkileşimleri)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (Kladribin etiketi, İlaç etkileşimleri)